OncoSec Medical Inc.
200 South Virginia Street
8th Floor
Reno
Nevada
89501
United States
Tel: 775-562-0504
Website: http://www.oncosec.com/
Email: investors@oncosec.com
410 articles about OncoSec Medical Inc.
-
OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020
8/25/2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor , President and Chief Executive Officer will present at the LD 500 Virtual Conference on Wednesday, September 2, 2020 . The prese
-
OncoSec Medical Incorporated Announces Pricing of Public Offering - Aug 17, 2020
8/17/2020
OncoSec Medical Incorporated announced that in connection with its previously announced offering of common stock, it has entered into purchase agreements for the purchase of an aggregate 4,608,589 shares of the Company at an offering price of $3.25 per share for aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.
-
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock - Aug 15, 2020
8/15/2020
OncoSec Medical Incorporated announced that it intends to offer and sell shares of its common stock in a public offering.
-
OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020
8/10/2020
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor , President and Chief Executive Officer will present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11 , 2020
-
OncoSec Appoints Kellie Malloy Foerter as Chief Operating Officer
7/27/2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced that Kellie Malloy Foerter , previously Chief Clinical Development Officer, has been appointed Chief Operating Officer, effective immediately. W
-
OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon
7/13/2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced the promising potential of its novel DNA–encodable vaccine candidate, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19
-
OncoSec to be Featured in "Grand Rounds: a Webinar in Biotech and Specialty Pharma," Webinar Hosted by Alliance Global Partners
7/9/2020
OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company will be featured in a live webinar, "Grand Rounds: A Webinar in Biotech and Specialty Pharma," hosted by James Molloy , Managing Director of Equi
-
OncoSec Set to Join Russel Microcap® Index
6/24/2020
OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company is set to join the Russell Microcap ® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market o
-
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
6/22/2020
New Data Highlights the Flexibility of OncoSec's Therapeutic Platform to Enable Greater Anti-Tumor Activity with the Next-Generation TAVO PLUS IL-12 Plasmid PENNINGTON, N.J. and SAN DIEGO , June 22, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today p
-
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy
6/9/2020
- Tumor Shrinkage and Related Clinical Responses Observed in KEYNOTE-890 in Heavily Pretreated mTNBC Patients Supports Moving to a First-Line Treatment
-
OncoSec to Present at Virtual Summer Investor Summit
6/4/2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor , President and Chief Executive Officer of OncoSec, will present a company overview at the Virtual Summer Investor Summit on Tuesday, J
-
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System
5/27/2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance for three new patent applications covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO
-
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
5/21/2020
OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical data demonstrating the utility of OncoSec's next-generation product candidate, TAVO PLUS (enhanced interleukin-12 or "IL
-
OncoSec Partners with the Melanoma Research Foundation to Host Live Panel Discussion during Melanoma Awareness Month
5/14/2020
OncoSec launches broader #TogetherAgainstCancer campaign and is proud to partner with melanoma advocacy partners throughout the month of May [14-May-2020] PENNINGTON, N.J. and SAN DIEGO , May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its partnering w
-
OncoSec's TAVO™ Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma
5/13/2020
OncoSec Medical Incorporated (Nasdaq:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the European Medicines Agency (EMA) issued an advanced therapy medicinal product (ATMP) certificate for chemistry manufacturing controls (CMC) data covering its l
-
OncoSec's TAVO™ in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'
5/6/2020
Oncosec Medical Incorporated (the "Company" or "Oncosec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced published data in Clinical Cancer Research, linked here, that demonstrated its lead product candidate, TAVO™ (interleukin-12 or "IL-12" plasmid), in combination with the anti-PD-1 checkpoint inhibitor KEYTRUDA
-
BioSpace Movers & Shakers, April 24
4/24/2020
Biopharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers. -
OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO™ Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting
4/21/2020
OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced pre-clinical data from a feasibility study of its visceral lesion applicator (VLA) electroporation device and APOLLO generator which were presented online at the Annual Meeting of the Society of Interventional Radiology (SIR).
-
OncoSec Appoints Renowned Oncologist and Immunologist, Herbert Kim Lyerly, M.D., Duke University, to its Board of Directors
4/20/2020
Avtar Dhillon, M.D., Resigns as Chair of the Board; Current Board Member, Margaret R. Dalesandro, Ph.D., Assumes the Role of Chair
-
Clinical Catch-Up: April 6-10
4/13/2020
It was a very busy week for clinical trial news. Here’s a look.